Related Experiment Video
Updated: May 11, 2026

Acupoint Catgut Embedding Therapy in Traditional Chinese Medicine for Managing Allergic Rhinitis
Published on: December 20, 2024
Prevalence of hypothalamic-pituitary-adrenal axis suppression in children treated for asthma with inhaled
Ryan W Smith1, Kim Downey, Michelle Gordon
1Department of Medicine and Health, University College Cork, Cork, Ireland;
Insights
Inhaled corticosteroids (ICS) can cause hypothalamic-pituitary-adrenal (HPA) axis suppression in children with asthma. Regular screening for HPA axis suppression is recommended, especially for those on high-dose ICS.
Area of Science:
- Pediatric Endocrinology
- Respiratory Medicine
- Pharmacology
Background:
- Asthma management often involves inhaled corticosteroids (ICS).
- Long-term ICS use may impact the hypothalamic-pituitary-adrenal (HPA) axis.
- HPA axis suppression is a potential concern in children receiving ICS therapy.
Purpose of the Study:
- To investigate the prevalence of HPA axis suppression in pediatric asthma patients using ICS.
- To identify risk factors associated with HPA axis suppression in this population.
Main Methods:
- A cohort of 214 children with asthma on ICS was studied.
- HPA axis suppression was assessed via morning serum cortisol and ACTH stimulation tests.
- Clinical and demographic data were collected for analysis.
Main Results:
- HPA axis suppression was detected in 9.3% of the children studied.
- Increased ICS dosage correlated significantly with higher odds of HPA axis suppression.
- Suppression was observed in children using 200-500 μg/day of ICS, with no prediction by drug type or duration.
Conclusions:
- Laboratory evidence confirms HPA axis suppression in children treated with ICS for asthma.
- Routine screening for HPA axis suppression is advised for children on high-dose ICS (>500 μg/day).
- Screening may also be beneficial for children on medium-dose ICS.
Objective:
To determine the prevalence of hypothalamic-pituitary-adrenal (HPA) axis suppression in asthmatic children on inhaled corticosteroids (ICS).
Methods:
Clinical and demographic variables were recorded on preconstructed, standardized forms. HPA axis suppression was measured by morning serum cortisol levels and confirmed by low-dose adrenocorticotropic hormone stimulation testing.
Results:
In total, 214 children participated. Twenty children (9.3%, 95% CI 5.3% to 13.4%) had HPA axis suppression. Odds of HPA axis suppression increased with ICS dose (OR 1.005, 95% CI 1.003 to 1.009, P<0.001). All children with HPA axis suppression were on a medium or lower dose of ICS for their age (200 μg/day to 500 μg/day). HPA axis suppression was not predicted by drug type, dose duration, concomitant use of long-acting beta-agonist or nasal steroid, or clinical features.
Conclusion:
Laboratory evidence of HPA axis suppression exists in children taking ICS for asthma. Children should be regularly screened for the presence of HPA axis suppression when treated with high-dose ICS (>500 μg/day). Consideration should be given to screening children on medium-dose ICS.
Related Concept Videos
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
Cushing Syndrome II: Pathophysiology
Adrenal Gland Disorders
Adrenal insufficiency, characterized by insufficient cortisol and aldosterone production, leads to conditions like Addison's disease. This disorder, affecting the adrenal cortex, exhibits symptoms such as skin bronzing, dehydration, low blood pressure, fatigue, and weight loss. Congenital adrenal hyperplasia, a genetic ailment causing...
Cushing Syndrome I: Introduction
Asthma III: Clinical Manifestations
Asthma-I: Introduction

